Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Cord Blood Announces $65 Million Investment from KKR

publication date: Apr 13, 2012

China Cord Blood Corp., the largest operator of cord blood banks in China, raised $65 million in new cash from Kohlberg Kravis Roberts. KKR made the investment through its China Growth Fund LLP, which bought $65 million of 5-year convertible bonds. It is the fund's first healthcare investment. The bonds pay 7% face amount, though other conditions can increase that rate, and they convert into common stock at roughly today's market price. More details....

Stock Symbol:   (NYSE: CO)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital